PMID- 31596144
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 15
IP  - 33
DP  - 2019 Nov
TI  - Healthcare resource utilization and costs of adverse events among patients with 
      metastatic urothelial cancer in USA.
PG  - 3809-3818
LID - 10.2217/fon-2019-0434 [doi]
AB  - Aim: To estimate incremental costs and healthcare resource utilization (HRU) 
      associated with select severe adverse events (AEs) and AEs of any severity in 
      patients with metastatic urothelial carcinoma receiving first-line (1L) therapy. 
      Materials & methods: Adults treated with 1L systemic therapy between January 2012 
      and September 2017 with >/=1 urothelial cancer diagnosis were identified using 
      claims data. Per-patient-per-month cost differences and HRU rate ratios comparing 
      patients with and without select AEs were estimated. Results: Patients with any 
      severe select AEs had higher costs than those without (cost difference = $6130 
      per-patient-per-month; p < 0.001). Healthcare costs and HRU for patients with 
      select AEs were significantly higher versus those without. Conclusion: Select AEs 
      during 1L therapy for metastatic urothelial carcinoma can result in significant 
      burden to patients and healthcare systems.
FAU - Grivas, Petros
AU  - Grivas P
AD  - Fred Hutchinson Cancer Research Center, University of Washington; Seattle Cancer 
      Care Alliance, Seattle, WA 98109, USA.
FAU - DerSarkissian, Maral
AU  - DerSarkissian M
AD  - Analysis Group, Inc., Boston, MA 02199, USA.
FAU - Shenolikar, Rahul
AU  - Shenolikar R
AD  - AstraZeneca US, Gaithersburg, MD 20878, USA.
FAU - Laliberte, Francois
AU  - Laliberte F
AD  - Groupe d'analyse, Ltee, Montreal, QC, H3B 0G7, Canada.
FAU - Doleh, Yunes
AU  - Doleh Y
AD  - AstraZeneca US, Gaithersburg, MD 20878, USA.
FAU - Duh, Mei Sheng
AU  - Duh MS
AD  - Groupe d'analyse, Ltee, Montreal, QC, H3B 0G7, Canada.
LA  - eng
PT  - Journal Article
DEP - 20191009
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
SB  - IM
MH  - Administrative Claims, Healthcare/statistics & numerical data
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Carcinoma, Transitional Cell/*drug therapy/pathology
MH  - Drug-Related Side Effects and Adverse 
      Reactions/*economics/epidemiology/etiology/therapy
MH  - Female
MH  - Health Care Costs/*statistics & numerical data
MH  - Health Resources/economics/statistics & numerical data
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - Retrospective Studies
MH  - United States/epidemiology
MH  - Urinary Bladder Neoplasms/*drug therapy/pathology
MH  - Urothelium/pathology
OTO - NOTNLM
OT  - bladder cancer
OT  - chemotherapy toxicity
OT  - health care costs
OT  - immunotherapy-related adverse events
OT  - urologic carcinoma
EDAT- 2019/10/10 06:00
MHDA- 2020/04/03 06:00
CRDT- 2019/10/10 06:00
PHST- 2019/10/10 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
PHST- 2019/10/10 06:00 [entrez]
AID - 10.2217/fon-2019-0434 [doi]
PST - ppublish
SO  - Future Oncol. 2019 Nov;15(33):3809-3818. doi: 10.2217/fon-2019-0434. Epub 2019 
      Oct 9.